Forward Pharma A/S (FWP)
|Net Income (ttm)||-4.22M|
|Trading Day||March 4|
|Day's Range||7.14 - 8.09|
|52-Week Range||4.61 - 12.72|
Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions
COPENHAGEN, Denmark, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to ongoing precautionary measures against th...
There are investors who purchase shares of stocks that are trading below their liquidation value in the belief that they can make huge gains out of their investments after the market has reass...
Forward Pharma: Heads You Win Big, Tails You Still Win
COPENHAGEN, Denmark, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the n...
COPENHAGEN, Denmark, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced that Chief Executive Officer, Dr. Claus Bo Svendsen, will participate ...
Forward Pharma A/S, a biopharmaceutical company, focuses on developing proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. The company was founded in 2005 and is headquartered in Copenhagen, Denmark.
|Stock Exchange |
|Ticker Symbol |